Atlantic Private Wealth
ALNY icon

Atlantic Private Wealth’s Alnylam Pharmaceuticals ALNY Stock Holding History

Atlantic Private Wealth’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-1
Closed -$301 – 304
2026
Q2 		$301 Hold
1
– – ﹤0.01% 290
2026
Q1 		$331 Hold
1
– – ﹤0.01% 297
2025
Q4 		$398 Buy
+1
New +$443 ﹤0.01% 347

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Atlantic Private Wealth's ALNY Position: Q3 2026 in Review

Atlantic Private Wealth sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2026, closing a stake of 1 share — an estimated $301 sold.

Atlantic Private Wealth first reported a position in ALNY in Q4 2025 and held it in 3 quarters. The position peaked at $398 in Q4 2025. 403 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

  • Atlantic Private Wealth reported no remaining Alnylam Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Atlantic Private Wealth sold 1 Alnylam Pharmaceuticals share in Q3 2026, an estimated $301.
  • Atlantic Private Wealth first reported a position in Alnylam Pharmaceuticals in Q4 2025 and held it in 3 quarters.
  • Atlantic Private Wealth's Alnylam Pharmaceuticals position peaked at $398 in Q4 2025.
  • 403 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on Atlantic Private Wealth's 13F filing for Q3 2026, filed 9 Nov 2026.